A Dose Escalation Study of the Combination of Lenalidomide (Revlimid速), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma
The purpose of this study is to determine the maximum tolerated dose (MTD) and to evaluate the safety of cyclophosphamide when given on days 1 and 8 in a 28 day cycle in doses starting at 300mg ranging to 700mg in combination with Lenalidomide (Revlimid速) plus dexamethasone in patients who present with relapsed or refractory myeloma.
Multiple Myeloma
DRUG: Lenalidomide|DRUG: Dexamethasone|DRUG: Cyclophosphamide
Dose limiting toxicity defined as: a) NCI Grade 4 haematological toxicity b) NCI Grade 他 non-haematological toxicity, Weekly for first cycle|Safety (type, frequency, severity, and relationship of adverse events), Weekly for first cycle then monthly
Time to progression, Monthly|Paraprotein response, Monthly|Bone marrow response, Baseline, end of treatment and disease progression|Duration of response, Monthly|Overall survival, Monthly
The purpose of this study is to determine the maximum tolerated dose (MTD) and to evaluate the safety of cyclophosphamide when given on days 1 and 8 in a 28 day cycle in doses starting at 300mg ranging to 700mg in combination with Lenalidomide (Revlimid速) plus dexamethasone in patients who present with relapsed or refractory myeloma.